Stock Ratings / Health Care / BMRA / news

TRIB (56) CDIO (31) QCLS (42) VRAX (58) ⌘ Pro Terminal →

Why BMRA Stock slipped -0.57% Today — RQD Quant Desk Flash

$1.74 -0.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Biomerica Inc. (BMRA) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $8.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BMRA)Realized 20D OHLCV Swing Band: ±12%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why BMRA Stock slipped -0.57% Today — RQD Quant Desk Flash

Biomerica Inc. (BMRA) slipped -0.57% to $1.74, trading at 19% of its 52-week range ($1.45 – $2.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 19% of its 52-week range ($1.45 – $2.94) with RSI-14 at 37 (NEUTRAL RANGE).
▸Volatility Profile: Historical 20-day realized swing band of ±12% around $1.74 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D- (Sell) backed by 8.1% gross margin and $0 annual free cash flow.

Live BMRA Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BMRA)

✓Walkthrough of BMRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BMRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.18%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.71H $1.74L $1.68C $1.74VOL 10.2K

RES: $2.95SUP: $1.62SMA50: $2.06SMA200: $2.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BMRA Butterfly Map → + Track BMRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -16.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BMRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BMRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BMRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMRA)

Health Care Rank #685 of 1016 ⚔️ TRIB vs BMRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BMRA vs. TRIB, CDIO, QCLS, VRAX)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Biomerica Inc. (BMRA) ranks #685 by composite RQD confidence (39/100, grade D-) and #911 by equity capitalization ($8.0M). Within this direct 5-issuer industry benchmark cohort, BMRA leads on earnings valuation at N/A trailing P/E, while BMRA leads on capital efficiency and profitability with -35.0% ROIC and 8.1% gross margin. VRAX currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with BMRA at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BMRA ACTIVE Biomerica Inc.	D-	39/100	—	8.1%	-35.0%	-0.57%	$8.0M	Benchmark Subject
TRIB Trinity Biotech plc	D+	56/100	—	—	—	-2.50%	$5.4M	/trib-vs-bmra →
CDIO Cardio Diagnostics Holdings Inc.	E	31/100	—	—	-35.0%	+2.94%	$5.2M	/cdio-vs-bmra →
QCLS Q/C Technologies Inc.	D-	42/100	—	—	-35.0%	-3.44%	$3.6M	/qcls-vs-bmra →
VRAX Virax Biolabs Group Limited	D+	58/100	—	—	—	+10.00%	$1.8M	/vrax-vs-bmra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0000073290

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Biomerica Inc. (BMRA) reported GAAP revenue of $4.5M (-16.2% vs. FY2024 revenue of $5.3M , and -17.8% cumulative change since FY2023) , GAAP net income of -$3.8M, operating cash flow of -$3.4M, and free cash flow of -$3.4M (+11.0% YoY). On the balance sheet, BMRA closed FY2025 with $6.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$4.5M	-$3.8M	-$3.4M	-$3.4M	$6.0M	—
FY2024 (FY)	2025-05-31	$5.3M	-$5.0M	-$3.8M	-$3.8M	$7.3M	—
FY2023 (FY)	2024-05-31	$5.4M	-$6.0M	-$5.4M	-$5.4M	—	—

3. BMRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Biomerica Inc. (NASDAQ: BMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.74 (-0.57% 1D, market cap $8.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BMRA ranks #685 in composite RQD confidence.

How does BMRA compare to TRIB and CDIO in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), BMRA carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 8.1%, and ROIC of -35.0%. By comparison, TRIB (Trinity Biotech plc) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $5.4M) and CDIO (Cardio Diagnostics Holdings Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M). Among the 5-stock peer group, BMRA leads on earnings multiple (N/A) while BMRA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BMRA?

Per BMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000073290), Biomerica Inc. generated $4.5M in revenue (-16.2% YoY), -$3.8M in net income, and -$3.4M in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BMRA trading relative to its 50-day, 200-day, and 52-week technical levels?

BMRA last traded at $1.74 (-0.57% on volume of 4,231 shares), positioning the stock -15.53% below its 50-day simple moving average ($2.06) and -15.12% below its 200-day simple moving average ($2.05). Across its 52-week range of $1.45 to $2.94, BMRA sits at the 19.5% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.53 to $1.95).

BMRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is BMRA stock moving today?

Why BMRA Stock slipped -0.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: BMRA RQD Cockpit BMRA 12M Forecast BMRA Earnings & Move BMRA Dividends & DRIP BMRA Insiders & 13F BMRA Whale Options BMRA Profit Sankey BMRA News & Why